Mentari adds $200M to migraine mission; Royalty's latest ATTR-CM deal
Another $200M for Mentari: Migraine drug developer Mentari Therapeutics has lined up a second private placement as it works to close its reverse merger with InMed Pharmaceuticals. The Paragon Therapeutics spinout ...
July 22, 2026 10:17 AM EDT News Briefing Mentari adds $200M to migraine mission; Royalty's latest ATTR-CM deal Kyle LaHucik Biotech Correspondent Another $200M for Mentari: Migraine drug developer Mentari Therapeutics has lined up a second private placement as it works to close … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that